Shin Nippon's migraine treatment spinoff, Satsuma Pharmaceuticals, floated above its range to raise $82.5m in an offering that follows $86m of funding.

Osage University Partners has celebrated an exit as migraine treatment developer Satsuma Pharmaceuticals listed on the Nasdaq Global Market following an $82.5m offering.

The SoftBank-backed biological analysis technology provider priced its shares above its range and will likely close the offering at $449m.

The immuno-oncology drug developer, spun out of Johannes Gutenberg University Mainz, has filed for a $100m offering in the US.

Praktikertjänst-backed Aprea Therapeutics has filed for a $68.3m initial public offering that will fund the clinical progress of its cancer drug candidates.

The immuno-oncology drug developer, which counts numerous pharmaceutical firms among its investors, has filed for a $100m offering in the US.

Karolinska Institute spinout Aprea Therapeutics has filed to raise approximately $68.3m in an IPO that will see it list on the Nasdaq Global Select Market.

Fosun Pharma is in line to exit Shanghai Henlius Biotech, which has set a price range for an offering that could raise up to $477m.

Spirogen spinoff ADC will put the proceeds into advancing its cancer-fighting antibody drug conjugates, having raised more than $530m from backers including AstraZeneca.

Emtek could potentially exit online real estate platform PropertyGuru, which is reportedly preparing an initial public offering in Australia.